Reply

Ultrasound in Obstetrics and Gynecology

Volumn 45, Issue 6, 2015, Pages 755-757

  Akolekar, R ^a,b,c   Beta, J ^a   Picciarelli, G ^a   Ogilvie, C ^c   D'Antonio, F ^d  

^a MEDWAY MARITIME HOSPITAL   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABORTION, SPONTANEOUS; ADVERSE EFFECTS; AMNIOCENTESIS; CHORION VILLUS SAMPLING; FEMALE; HUMAN; PREGNANCY; PRENATAL DIAGNOSIS;

ABORTION, SPONTANEOUS; AMNIOCENTESIS; CHORIONIC VILLI SAMPLING; FEMALE; HUMANS; PREGNANCY; PRENATAL DIAGNOSIS;

EID: 84930338126     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.14851     Document Type: Letter

References (13)

1. Akolekar R, Beta J, Picciarelli G, Ogilve C, D'Antonio F,. Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis. Ultrasound Obstet Gynecol 2015; 45: 16-26.
2. Morris JK, Springett A., The National Down Syndrome Cytogenetic Register for England and Wales 2012. Annual Report. Queen Mary University of London, Barts and The London School of Medicine and Dentistry. 2014. http://www.binocar.org/content/annrep2012-final.pdf [Accessed 26th February 2015].
3. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH,. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin, and pregnancy associated plasma protein-A. Ultrasound Obstet Gynecol 2008; 31: 618-624.
4. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH,. Maternal age- and gestation specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167-170.
5. Won RH, Currier RJ, Lorey F, Towner DR,. The timing of demise in fetuses with trisomy 21 and trisomy 18. Prenat Diagn 2005; 25: 608-611.
6. Muller F, Thibaud D, Poloce F, Gelineau MC, Bernard M, Brochet C, Millet C, Real JY, Dommergues M., Risk of amniocentesis in women screened positive for Down syndrome with second trimester maternal serum markers. Prenat Diagn 2002; 22: 1036-1039.
7. Kong CW, Leung TN, Leung TY, Chan LW, Sahota DS, Fung TY, Lau TK,. Risk factors for procedure-related fetal losses after mid-trimester genetic amniocentesis. Prenat Diagn 2006; 26: 925-930.
8. Pitukkijronnakorn S, Promsonthi P, Panburana P, Udomsubpayakul U, Chittacharoen A,. Fetal loss associated with second trimester amniocentesis. Arch Gynecol Obstet 2011; 284: 793-797.
9. Bartolucci A, Hillegass W., Overview, strengths, and limitations of systematic reviews and meta-analyses. In Evidence-Based Practice: Toward Optimizing Clinical Outcomes, Chiappelli F, Caldeira Brant XM, Neagos N, Oluwadara O, Ramchandani M, (eds). DOI: 10.1007/978-3-642-05025-1-2. Springer-Verlag: Berlin, Heidelberg, 2010; 17-33.
10. Eddleman KA, Malone FD, Sullivan L, Dukes K, Berkowitz RL, Kharbutli Y, Porter TF, Luthy DA, Comstock CH, Saade GR, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME,. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108: 1067-1072.
11. Towner D, Currier RJ, Lorey FW, Cunningham GC, Greve LC,. Miscarriage risk from amniocentesis performed for abnormal maternal serum screening. Am J Obstet Gynecol 2007; 196: 608.e1-5.
12. Odibo AO, Gray DL, Dicke JM, Stamilio DM, Macones GA, Crane JP,. Revisiting the fetal loss rate after second-trimester genetic amniocentesis: a single center's 16-year experience. Obstet Gynecol 2008; 111: 589-595.
13. Corrado F, Cannata ML, La Galia T, Magliarditi M, Imbruglia L, D'anna R, Carlo Stella N,. Pregnancy outcome following mid-trimester amniocentesis. J Obstet Gynaecol 2012; 32: 117-119.